Studies have reported that miR-27a and miR-155 target SMAD2 and SMAD4, which may lead to downregulation of TGF-β1 in some cancers, which is important for modulating the antitumor effects of the pathway in early-stage tumors [61,62]. Here, SMAD2 is linked to cancer.